Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer

被引:106
|
作者
Jentzen, Walter [1 ]
Freudenberg, Lutz [1 ]
Eising, Emst G. [1 ]
Sormenschein, Wilfried [1 ]
Knust, Jochen [1 ]
Bockisch, Andreas [1 ]
机构
[1] Univ Duisburg Essen, Klin Nukl Med, D-45122 Essen, Germany
来源
JOURNAL OF NUCLEAR MEDICINE | 2008年 / 49卷 / 06期
关键词
PET; radionuclide therapy; dosimetry; iodine-124; differentiated thyroid cancer;
D O I
10.2967/jnumed.107.047159
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Iodine kinetics and lesion dose per administered I-131 activity (LDpA) of differentiated thyroid cancer metastases were determined using I-124 PET. These data were analyzed to derive an optimized dosimetry protocol. Methods: We evaluated the time-activity-concentration curves of 37 lesions in 17 patients who had undergone thyroidectomies. LDpA determination involved I-124 PET images acquired at 4, 24, 48, 72, and 96 h after intake of a capsule containing 20-40 MBq of I-124. A combination of a linear and a monoexponential or a monoexponential function only parameterized the time-activity-concentration curves. The LDpAs, calculated using data from all 5 PET time points, served as reference. The lesions were classified into 3 groups, according to potential for cure with I-131 therapy: low (<= 5 Gy GBq(-1); n = 14), medium (between 5 and 10 Gy GBq(-1); n = 9), or high LDpAs (>10 Gy GBq(-1); n = 14). Using the reference approach, the differences in the empiric kinetic parameters within the LDpA groups were evaluated. The reference LDpAs were compared with those derived from only 2, 3, or 4 PET data points and from 1 adapted 2-point approach. Lin's concordance correlation coefficient (rho(c)) and the mean absolute percentage deviation in LDpAs were used to assess agreement between simplified and reference approaches. Results: The effective I-124 half-life, linear activity-concentration rate (alpha), and 24-h activity concentration (CpA) (the latter 2 per administered I-124 activity) differed significantly among the LDpA groups (P < 0.05). LDpAs correlated with 24-h CpAs (r = 0.94, P < 0.001). Using the 4-, 24-, and 96-h measurements, a rho(c) value of greater than or equal to 0.90 was found, and the mean absolute percentage deviation was less than or equal to 16%. Similar statistical values were obtained for the adapted approach, which was based on 24- and 96-h PET data points only. Conclusion: Lesion classification into LDpA groups was feasible using a single PET scan at similar to 24 h. Because of the highly variable kinetics, 1 additional measurement at similar to 96 h was needed to obtain a sufficiently reliable LDpA estimate. The adapted 24-96-h approach appears to be the optimal I-124 protocol and is a reliable simplification of the 5-point protocol.
引用
收藏
页码:1017 / 1023
页数:7
相关论文
共 50 条
  • [1] The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancer
    Weber, Manuel
    Binse, Ina
    Nagarajah, James
    Bockisch, Andreas
    Herrmann, Ken
    Jentzen, Walter
    [J]. QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 63 (03): : 235 - 252
  • [2] Evaluation of 124I PET/CT and 124I PET/MRI in the management of patients with differentiated thyroid cancer
    Dercle, Laurent
    Deandreis, Desiree
    Terroir, Marie
    Leboulleux, Sophie
    Lumbroso, Jean
    Schlumberger, Martin
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (06) : 1006 - 1010
  • [3] Evaluation of 124I PET/CT and 124I PET/MRI in the management of patients with differentiated thyroid cancer
    Laurent Dercle
    Désirée Deandreis
    Marie Terroir
    Sophie Leboulleux
    Jean Lumbroso
    Martin Schlumberger
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43 : 1006 - 1010
  • [4] Quantitative performance evaluation of 124I PET/MRI lesion dosimetry in differentiated thyroid cancer
    Wierts, R.
    Jentzen, W.
    Quick, H. H.
    Wisselink, H. J.
    Pooters, I. N. A.
    Wildberger, J. E.
    Herrmann, K.
    Kemerink, G. J.
    Backes, W. H.
    Mottaghy, F. M.
    [J]. PHYSICS IN MEDICINE AND BIOLOGY, 2018, 63 (01):
  • [5] Differentiated thyroid carcinoma: Diagnosis and dosimetry using 124I PET/CT
    Capoccetti F.
    Biggi E.
    Rossi G.
    Manni C.
    Brianzoni E.
    [J]. Clinical and Translational Imaging, 2013, 1 (3) : 185 - 193
  • [6] 124I PET Assessment of Response of Bone Metastases to Initial Radioiodine Treatment of Differentiated Thyroid Cancer
    Jentzen, Walter
    Verschure, Femke
    van Zone, Annelie
    van de Kolk, Rudie
    Wierts, Roel
    Schmitz, Jochen
    Bockisch, Andreas
    Binse, Ina
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (10): : 1499 - 1504
  • [7] The effectiveness of 124I PET/CT in patients with differentiated thyroid cancer
    Capoccetti, F.
    Criscuoli, B.
    Rossi, G.
    Ferretti, F.
    Manni, C.
    Brianzoni, E.
    [J]. QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 53 (05): : 536 - 545
  • [8] Assessment of Lesion Response in the Initial Radioiodine Treatment of Differentiated Thyroid Cancer Using 124I PET Imaging
    Jentzen, Walter
    Hoppenbrouwers, Jan
    van Leeuwen, Paul
    van der Velden, Daan
    van de Kolk, Rudie
    Poeppel, Thorsten Dirk
    Nagarajah, James
    Brandau, Wolfgang
    Bockisch, Andreas
    Rosenbaum-Krumme, Sandra
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (11): : 1759 - 1765
  • [9] Assessment of lesion response in differentiated thyroid cancer patients undergoing radioiodine treatment using 124I PET/CT
    Wierts, R.
    Brans, B.
    Havekes, B.
    Halders, S. G. E. A.
    Mottaghy, F. M.
    Jentzen, W.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S37 - S38
  • [10] Absolute Recovery Coefficients in 124I PET/CT Imaging in 131I Radioiodine Therapy of Thyroid Cancer
    Pigotti, G.
    Martini, D.
    Villano, C.
    De Francesco, V.
    Baldassarrini, E.
    Panichelli, P.
    Valentini, G.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S253 - S253